report_id=bw10050 Heart failure therapeutics are observing an upward trajectory, spurred by an aging population increasingly susceptible to cardiac conditions. Advances in medical technology are ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced a significant advancement in its cardiovascular ...

In response to the increased utilization of Barostim therapy and the strong evidence supporting its clinical outcomes, the ...

Johnson & Johnson (J&J) has announced the completion of its acquisition of V-Wave, a company specialising in the development ...

Recent research has found that adhering to a Mediterranean diet can help lower the risk of heart failure – and this is ...

The Keck School of Medicine of USC has launched a strategic collaboration with StemCardia, a biotechnology company, founded by a Keck School of Medicine faculty member, that develops cellular and ...

Three common cardiovascular diseases in adults—heart failure, atrial fibrillation and coronary heart disease—are linked to ...

USV introduces OnArni, a cost-effective heart failure medication at ₹8 per tablet, improving adherence and health outcomes.

Most of us are familiar with Ozempic as a treatment for type 2 diabetes and obesity but now, new findings suggest that ...

The results of this study suggest that there are specialty-related differences in treatment patterns for CHF patients admitted to our institution. Patient characteristics were similar between ...

For a range of hospitalized patients at risk of worsening heart failure (HF), tying medical interventions to cardiac ...

Women are still being excluded from cardiovascular research trials, and it has a lasting impact on heart disease treatment ...